V

VistaGen Therapeutics Inc
NASDAQ:VTGN

Watchlist Manager
VistaGen Therapeutics Inc
NASDAQ:VTGN
Watchlist
Price: 2.82 USD -3.75% Market Closed
Market Cap: 76.3m USD
Have any thoughts about
VistaGen Therapeutics Inc?
Write Note

VistaGen Therapeutics Inc
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

VistaGen Therapeutics Inc
Research & Development Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
V
VistaGen Therapeutics Inc
NASDAQ:VTGN
Research & Development
-$23.5m
CAGR 3-Years
-13%
CAGR 5-Years
-5%
CAGR 10-Years
-27%
Abbvie Inc
NYSE:ABBV
Research & Development
-$7.9B
CAGR 3-Years
-4%
CAGR 5-Years
-9%
CAGR 10-Years
-10%
Gilead Sciences Inc
NASDAQ:GILD
Research & Development
-$5.5B
CAGR 3-Years
-4%
CAGR 5-Years
10%
CAGR 10-Years
-9%
Amgen Inc
NASDAQ:AMGN
Research & Development
-$5.8B
CAGR 3-Years
-7%
CAGR 5-Years
-8%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Research & Development
-$3.5B
CAGR 3-Years
-7%
CAGR 5-Years
-15%
CAGR 10-Years
-14%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Research & Development
-$4.9B
CAGR 3-Years
-20%
CAGR 5-Years
-14%
CAGR 10-Years
-15%

See Also

What is VistaGen Therapeutics Inc's Research & Development?
Research & Development
-23.5m USD

Based on the financial report for Jun 30, 2024, VistaGen Therapeutics Inc's Research & Development amounts to -23.5m USD.

What is VistaGen Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-27%

Over the last year, the Research & Development growth was 29%. The average annual Research & Development growth rates for VistaGen Therapeutics Inc have been -13% over the past three years , -5% over the past five years , and -27% over the past ten years .

Back to Top